Spyre Research And Ddevelopement To Revenue from 2010 to 2024
| SYRE Stock | 23.86 0.73 3.16% |
Research And Ddevelopement To Revenue | First Reported 2010-12-31 | Previous Quarter 101.02031603 | Current Value 106.07 | Quarterly Volatility 35.24031155 |
Check Spyre Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Spyre Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 1.1 M, Total Revenue of 841.7 K or Other Operating Expenses of 255.3 M, as well as many indicators such as Price To Sales Ratio of 176, Dividend Yield of 0.0 or PTB Ratio of 0.77. Spyre financial statements analysis is a perfect complement when working with Spyre Therapeutics Valuation or Volatility modules.
Spyre | Research And Ddevelopement To Revenue |
Latest Spyre Therapeutics' Research And Ddevelopement To Revenue Growth Pattern
Below is the plot of the Research And Ddevelopement To Revenue of Spyre Therapeutics over the last few years. It is the ratio of a company's research and development expenses to its total revenue, indicating how much of the revenue is invested back into developing new products or services. Spyre Therapeutics' Research And Ddevelopement To Revenue historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Spyre Therapeutics' overall financial position and show how it may be relating to other accounts over time.
| Research And Ddevelopement To Revenue | 10 Years Trend |
|
Research And Ddevelopement To Revenue |
| Timeline |
Spyre Research And Ddevelopement To Revenue Regression Statistics
| Arithmetic Mean | 18.03 | |
| Geometric Mean | 5.20 | |
| Coefficient Of Variation | 195.48 | |
| Mean Deviation | 23.75 | |
| Median | 3.05 | |
| Standard Deviation | 35.24 | |
| Sample Variance | 1,242 | |
| Range | 104 | |
| R-Value | 0.66 | |
| Mean Square Error | 754.62 | |
| R-Squared | 0.44 | |
| Significance | 0.01 | |
| Slope | 5.20 | |
| Total Sum of Squares | 17,386 |
Spyre Research And Ddevelopement To Revenue History
About Spyre Therapeutics Financial Statements
Spyre Therapeutics stakeholders use historical fundamental indicators, such as Spyre Therapeutics' Research And Ddevelopement To Revenue, to determine how well the company is positioned to perform in the future. Although Spyre Therapeutics investors may analyze each financial statement separately, they are all interrelated. For example, changes in Spyre Therapeutics' assets and liabilities are reflected in the revenues and expenses on Spyre Therapeutics' income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Spyre Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Research And Ddevelopement To Revenue | 101.02 | 106.07 |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Spyre Therapeutics is a strong investment it is important to analyze Spyre Therapeutics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Spyre Therapeutics' future performance. For an informed investment choice regarding Spyre Stock, refer to the following important reports:Check out the analysis of Spyre Therapeutics Correlation against competitors. For information on how to trade Spyre Stock refer to our How to Trade Spyre Stock guide.You can also try the Equity Valuation module to check real value of public entities based on technical and fundamental data.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Spyre Therapeutics. If investors know Spyre will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Spyre Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (37.90) | Return On Assets (0.39) | Return On Equity (0.92) |
The market value of Spyre Therapeutics is measured differently than its book value, which is the value of Spyre that is recorded on the company's balance sheet. Investors also form their own opinion of Spyre Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Spyre Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Spyre Therapeutics' market value can be influenced by many factors that don't directly affect Spyre Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Spyre Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Spyre Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Spyre Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.